Form 4: Palisade Bio CEO/CFO Granted 2M Restricted Stock Units

Palisade Bio's CEO and CFO, John David Finley, was granted 2,011,000 Restricted Stock Units, aligning executive incentives with shareholder value.

Summary

• John David Finley, serving as Director, 10% Owner, CEO, and CFO of PALISADE BIO, INC. (PALI), was granted 2,011,000 Restricted Stock Units (RSUs).
• The transaction date for this grant was February 9, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest with respect to 1/6th of the shares on July 6, 2026, and quarterly thereafter over the following 10 quarters.
• Vesting is subject to Mr. Finley's continuous service to the Issuer through each vesting date.
• Settlement of the RSUs may occur in cash if the Issuer does not have sufficient shares reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a generally positive development for aligning executive incentives with long-term company performance, though the potential for cash settlement introduces a slight uncertainty regarding the full alignment with stock appreciation.

Positives

• The grant of 2,011,000 Restricted Stock Units to the CEO and CFO aligns management's long-term interests with those of shareholders, incentivizing sustained company performance.
• The vesting schedule over approximately 2.5 years encourages continuous service and long-term strategic focus from key leadership.

Negatives

• The potential for RSUs to be settled in cash rather than common stock, if insufficient shares are reserved, could dilute the intended alignment of executive compensation with stock performance.
• The grant represents a significant number of potential shares (2,011,000), which could lead to future dilution for existing shareholders upon settlement in stock.

Risks

• There is a risk that the Issuer may not have sufficient shares reserved under its 2021 Equity Incentive Plan, which would necessitate cash settlement of the RSUs instead of common stock.
• The value of the RSUs is contingent on the company's future stock performance and Mr. Finley's continuous service, introducing performance and retention risks.

Future Outlook

The future outlook indicates that the granted Restricted Stock Units will vest quarterly over 10 quarters following the initial vesting on July 6, 2026, contingent upon the reporting person's continuous service. The ultimate settlement method (stock or cash) depends on the availability of shares reserved under the company's 2021 Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that Restricted Stock Unit grants are a standard component of executive compensation packages across various industries, particularly in biotechnology, designed to attract, retain, and incentivize key leadership. This grant to Palisade Bio's CEO and CFO is consistent with practices aimed at aligning executive performance with long-term shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if RSUs are settled in common stock, but also benefit from enhanced executive incentive for long-term performance.
• Employees: The CEO/CFO's compensation structure is tied to the company's long-term success, potentially influencing overall company culture and strategic direction.

Next Steps

• Continued service of John David Finley to the Issuer to meet vesting conditions.
• Vesting of 1/6th of the RSUs on July 6, 2026, followed by quarterly vesting over the subsequent 10 quarters.

Key Dates

Keywords

Restricted Stock Units, Executive Compensation, Insider Transaction, Form 4, Palisade Bio, PALI, CEO, CFO, Equity Incentive Plan, Vesting